Adoption of leading innovative platform spanning the Study Startup continuum key to stemming inefficiencies endemic in Industry
SAN FRANCISCO, September 26, 2017 -- goBalto, Inc., the leading provider of cloud-based clinical study startup (SSU) solutions, announced today that PSI CRO has chosen goBalto's complete suite of SSU applications for all studies on a worldwide basis to further bolster their clinical study startup process.
PSI CRO is a leading, full-service clinical research organization (CRO) that has been in business for over 20 years with one of the strongest track records in the industry. Recently ranked the number one global CRO by CenterWatch, over 90 percent of PSI's business comes from repeat customers who rely on their high performing teams that operate at some of the lowest turnover rates in the industry.
PSI CRO is using goBalto's Select to assist with site identification, feasibility assessment and selection of investigative sites. Identifying high-performing investigative sites is one of the most critical decisions made by a sponsor or CRO, it is a key driver in ensuring recruitment is completed on time and that the data is delivered in a timely manner with excellent quality. Select goes beyond simple aggregation of site data, providing a data driven approach to weighing selection and performance variables to aid in the identification of sites and target populations ideally suited to studies.
Study sites will then be seamlessly initiated for subject enrollment using goBalto's flagship product, Activate, which enhances real-time oversight to clinical operations management by tracking milestones on the critical path, and providing document workflow management capabilities in a transparent, regulatory-compliant, and user-friendly way. PSI CRO will leverage the advanced and comprehensive reporting capabilities of goBalto Analyze to provide real-time visibility into SSU activities across multiple studies and regions, making it easier to quantify team performance and discover meaningful patterns in study data.
Kirill Soldatov, Director of Process Improvement at PSI CRO stated, "The adoption of innovative technology to move into new markets and therapeutic areas and empower process improvements that lead to compress timelines is a core tenant of the PSI business strategy. The goBalto SSU platform is pivotal to these efforts."
"PSI recognizes the importance of being at the forefront of the technology adoption curve as a way to deliver efficiencies to clients. Ultimately, sponsors and CROs that capitalize on effective new technologies, will improve their stakeholder relations and thereby drastically increase the overall success of both their clinical trials and market position," said Jae Chung, goBalto's founder and president.